αII-Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe Traumatic Brain Injury Patients

In this study we assessed the clinical utility of quantitative assessments of alphaII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyze...

Full description

Saved in:
Bibliographic Details
Published inJournal of neurotrauma Vol. 27; no. 7; pp. 1203 - 1213
Main Authors Mondello, Stefania, Robicsek, Steven A., Gabrielli, Andrea, Brophy, Gretchen M., Papa, Linda, Tepas, Joseph, Robertson, Claudia, Buki, Andras, Scharf, Dancia, Jixiang, Mo, Akinyi, Linnet, Muller, Uwe, Wang, Kevin K.W., Hayes, Ronald L.
Format Journal Article
LanguageEnglish
Published United States Mary Ann Liebert, Inc 01.07.2010
Subjects
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers - cerebrospinal fluid
Brain
Brain Injuries - cerebrospinal fluid
Brain Injuries - diagnosis
Brain Injuries - mortality
Cerebrospinal fluid
Female
Humans
Injuries
Male
Middle Aged
Original
Peptide Fragments - cerebrospinal fluid
Physiological aspects
Predictive Value of Tests
Prognosis
Protein Isoforms - cerebrospinal fluid
Severity of Illness Index
Spectrin - cerebrospinal fluid
Survival Rate
Young Adult
United States
Online AccessGet full text

Cover

Abstract In this study we assessed the clinical utility of quantitative assessments of alphaII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score <or=8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6 h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24 h after injury. Within 24 h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6 ng/mL) and SBDP120 levels (>17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.
AbstractList In this study we assessed the clinical utility of quantitative assessments of alphaII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score &lt;or=8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6 h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24 h after injury. Within 24 h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (&gt;6 ng/mL) and SBDP120 levels (&gt;17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment. 
In this study we assessed the clinical utility of quantitative assessments of all-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score ≤8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6 h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24 h after injury. Within 24 h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6 ng/mL) and SBDP120 levels (>17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment. Key words: biomarkers; brain injury; diagnostic; outcome; neuronal death; spectrin breakdown products
In this study we assessed the clinical utility of quantitative assessments of αII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score ≤8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6 h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24 h after injury. Within 24 h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6 ng/mL) and SBDP120 levels (>17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.
In this study we assessed the clinical utility of quantitative assessments of alphaII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score <or=8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6 h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24 h after injury. Within 24 h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6 ng/mL) and SBDP120 levels (>17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.
In this study we assessed the clinical utility of quantitative assessments of all-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score ≤8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6 h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24 h after injury. Within 24 h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6 ng/mL) and SBDP120 levels (>17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.
In this study we assessed the clinical utility of quantitative assessments of alphaII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score <or=8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6 h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24 h after injury. Within 24 h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6 ng/mL) and SBDP120 levels (>17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.In this study we assessed the clinical utility of quantitative assessments of alphaII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score <or=8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6 h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24 h after injury. Within 24 h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6 ng/mL) and SBDP120 levels (>17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.
Audience Academic
Author Robicsek, Steven A.
Wang, Kevin K.W.
Papa, Linda
Hayes, Ronald L.
Gabrielli, Andrea
Buki, Andras
Muller, Uwe
Mondello, Stefania
Robertson, Claudia
Scharf, Dancia
Brophy, Gretchen M.
Akinyi, Linnet
Tepas, Joseph
Jixiang, Mo
Author_xml – sequence: 1
  givenname: Stefania
  surname: Mondello
  fullname: Mondello, Stefania
  organization: Department of Clinical Programs and Center of Innovative Research, and Department of Anesthesiology, University of Florida, Gainesville, Florida
– sequence: 2
  givenname: Steven A.
  surname: Robicsek
  fullname: Robicsek, Steven A.
  organization: Department of Anesthesiology, University of Florida, Gainesville, Florida
– sequence: 3
  givenname: Andrea
  surname: Gabrielli
  fullname: Gabrielli, Andrea
  organization: Department of Anesthesiology, University of Florida, Gainesville, Florida
– sequence: 4
  givenname: Gretchen M.
  surname: Brophy
  fullname: Brophy, Gretchen M.
  organization: Department of Pharmacy and Neurosurgery, Virginia Commonwealth Universitya, Richmond, Virginia
– sequence: 5
  givenname: Linda
  surname: Papa
  fullname: Papa, Linda
  organization: Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, Florida
– sequence: 6
  givenname: Joseph
  surname: Tepas
  fullname: Tepas, Joseph
  organization: Department of Surgery and Pediatrics, University of Florida, Jacksonville, Florida
– sequence: 7
  givenname: Claudia
  surname: Robertson
  fullname: Robertson, Claudia
  organization: Department of Critical Care, Baylor College of Medicine, Houston, Texas
– sequence: 8
  givenname: Andras
  surname: Buki
  fullname: Buki, Andras
  organization: Department of Neurosurgery, University of Pécs, Pécs, Hungary
– sequence: 9
  givenname: Dancia
  surname: Scharf
  fullname: Scharf, Dancia
  organization: Department of Research and Development, Banyan Biomarkers Inc., Alachua, Florida
– sequence: 10
  givenname: Mo
  surname: Jixiang
  fullname: Jixiang, Mo
  organization: Department of Research and Development, Banyan Biomarkers Inc., Alachua, Florida
– sequence: 11
  givenname: Linnet
  surname: Akinyi
  fullname: Akinyi, Linnet
  organization: Department of Research and Development, Banyan Biomarkers Inc., Alachua, Florida
– sequence: 12
  givenname: Uwe
  surname: Muller
  fullname: Muller, Uwe
  organization: Department of Research and Development, Banyan Biomarkers Inc., Alachua, Florida
– sequence: 13
  givenname: Kevin K.W.
  surname: Wang
  fullname: Wang, Kevin K.W.
  organization: Center of Innovative Research, Banyan Biomarkers Inc., and University of Florida, Department of Psychiatry, Gainesville, Florida
– sequence: 14
  givenname: Ronald L.
  surname: Hayes
  fullname: Hayes, Ronald L.
  organization: Department of Clinical Programs, Banyan Biomarkers Inc., and University of Florida, Department of Anesthesiology, Gainesville, Florida
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20408766$$D View this record in MEDLINE/PubMed
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-113425$$DView record from Swedish Publication Index
BookMark eNptkstqGzEUhkVJaRy3y27LQBdtF-PqMtcsCk7ciyEQg023QtEcuUpnJFeaSchj9UX6TD2Dk7SGSAiho-_8nNsJOXLeASGvGZ0xWtUfHQwzTscXL6tnZMLyvExrmvEjMsH_Mi1Zzo7JSYzXlDJR8PIFOeY0o1VZFBNi__xeLtP1DnQfrEvOAqifjb91ySr4ZtB9TN6vzxar-OE0WVi1dT7amCjXJJdDr30HCTqt4QYCJJughk71VqOKQvPSXQ_hLlmhCVwfX5LnRrURXt3fU7L58nlz_i29uPy6PJ9fpDrLeZ8WQuVZVtVaCKMMNVoBXGlORVHzIoM8V6bShua4GmMy3TSMK45M2VQNAzEl6V423sJuuJK7YDsV7qRXVi7s97n0YYtnkIyJjOfIf9rzCHfQaAw1qPbA7fDH2R9y628krzOOdUaBd_cCwf8aIPays1FD2yoHfoiyFBkVvKoEkm_35Fa1IK0zHgX1SMs5F6JkrMY8p2T2BIW7gc5qbL6xaD9wePN_Bo-hPzQZAbEHdPAxBjBS2x674seEbCsZleMoSRwlOY6SHEfpXyEfvR6En-b_AlH-zBk
CitedBy_id crossref_primary_10_1016_j_anrea_2016_09_007
crossref_primary_10_1007_s00414_021_02606_y
crossref_primary_10_1590_1980_57642015DN94000356
crossref_primary_10_1016_j_medine_2015_11_001
crossref_primary_10_1089_neu_2012_2631
crossref_primary_10_3390_biomedicines8100389
crossref_primary_10_1089_neu_2012_2478
crossref_primary_10_1089_neur_2021_0006
crossref_primary_10_1080_14737159_2021_2005583
crossref_primary_10_1016_j_neuropharm_2019_04_028
crossref_primary_10_1097_PCC_0000000000000059
crossref_primary_10_1371_journal_pone_0086472
crossref_primary_10_7759_cureus_77625
crossref_primary_10_1016_j_jneumeth_2016_04_026
crossref_primary_10_1212_WNL_0b013e3182904d43
crossref_primary_10_1093_toxsci_kfs224
crossref_primary_10_1111_jnc_12144
crossref_primary_10_1097_CM9_0000000000003061
crossref_primary_10_1586_erm_10_104
crossref_primary_10_1016_j_clineuro_2018_05_017
crossref_primary_10_1089_neu_2018_5898
crossref_primary_10_3390_diagnostics13101814
crossref_primary_10_3389_fneur_2015_00026
crossref_primary_10_1007_s13311_020_00840_7
crossref_primary_10_1038_nrneurol_2016_127
crossref_primary_10_1016_j_heliyon_2023_e22582
crossref_primary_10_2217_bmm_11_67
crossref_primary_10_1089_neu_2011_2171
crossref_primary_10_1016_j_medin_2015_11_008
crossref_primary_10_1080_14737159_2018_1428089
crossref_primary_10_4137_BMI_S9873
crossref_primary_10_1186_s13054_021_03698_z
crossref_primary_10_3390_jcm7030059
crossref_primary_10_3171_2018_4_PEDS17593
crossref_primary_10_1016_j_mehy_2017_06_016
crossref_primary_10_3390_biomedicines11123158
crossref_primary_10_1007_s12028_014_0028_2
crossref_primary_10_1371_journal_pone_0037599
crossref_primary_10_1038_nrneurol_2013_9
crossref_primary_10_2139_ssrn_3941039
crossref_primary_10_1371_journal_pone_0224952
crossref_primary_10_1016_j_wneu_2013_03_012
crossref_primary_10_1097_TA_0b013e31822117fe
crossref_primary_10_1109_RBME_2022_3161352
crossref_primary_10_1515_jvetres_2016_0053
crossref_primary_10_1007_s12035_016_9757_x
crossref_primary_10_1055_s_0040_1715095
crossref_primary_10_9758_cpn_2022_20_3_504
crossref_primary_10_1002_elps_201500585
crossref_primary_10_1089_neu_2018_5809
crossref_primary_10_1111_cns_12127
crossref_primary_10_3389_fneur_2017_00599
crossref_primary_10_1016_j_trsl_2021_12_009
crossref_primary_10_1016_j_expneurol_2015_11_012
crossref_primary_10_1007_s11481_023_10072_z
crossref_primary_10_1515_tjb_2017_0142
crossref_primary_10_1111_jnc_13534
crossref_primary_10_1089_neu_2011_1989
crossref_primary_10_3390_brainsci13111607
crossref_primary_10_1007_s00414_023_02990_7
crossref_primary_10_1038_nrdp_2016_84
crossref_primary_10_1016_j_brainres_2014_05_046
crossref_primary_10_1038_s41393_019_0319_8
crossref_primary_10_3389_fneur_2020_00249
crossref_primary_10_1089_neu_2012_2762
crossref_primary_10_1097_CCM_0000000000001284
crossref_primary_10_1002_elps_201200196
crossref_primary_10_1097_ACO_0b013e32834585d6
crossref_primary_10_1080_14737159_2024_2306876
crossref_primary_10_1371_journal_pone_0092698
crossref_primary_10_12786_bn_2017_10_e3
crossref_primary_10_1007_s12035_014_8898_z
crossref_primary_10_1016_j_cca_2018_10_025
crossref_primary_10_1186_cc13841
crossref_primary_10_1007_s12035_017_0424_7
crossref_primary_10_3390_ijms20205213
crossref_primary_10_1186_s13054_021_03503_x
crossref_primary_10_1097_SHK_0000000000002023
crossref_primary_10_3390_ijms160611903
crossref_primary_10_3390_molecules26206250
crossref_primary_10_1089_neu_2012_2825
crossref_primary_10_1016_j_bbr_2017_11_007
crossref_primary_10_1073_pnas_2024961118
crossref_primary_10_4103_bc_bc_27_16
crossref_primary_10_1007_s00701_020_04594_1
crossref_primary_10_1111_j_1471_4159_2011_07228_x
crossref_primary_10_1007_s00113_013_2542_7
crossref_primary_10_1089_neu_2014_3548
crossref_primary_10_1371_journal_pone_0080296
crossref_primary_10_3390_antiox9040297
crossref_primary_10_3390_cells9122698
crossref_primary_10_1155_2016_9746313
crossref_primary_10_1080_14728222_2018_1409723
crossref_primary_10_1016_j_accpm_2017_12_001
crossref_primary_10_1007_s12035_017_0821_y
crossref_primary_10_3109_02688697_2013_815317
crossref_primary_10_2217_fnl_15_13
crossref_primary_10_1016_j_exger_2015_06_003
crossref_primary_10_1177_0271678X17724681
crossref_primary_10_1089_neu_2011_2127
crossref_primary_10_1186_s13052_024_01744_4
crossref_primary_10_1007_s13670_012_0009_2
crossref_primary_10_3389_fneur_2018_00490
crossref_primary_10_1016_j_jeurea_2017_04_007
crossref_primary_10_1089_neu_2014_3672
crossref_primary_10_1517_17530059_2011_578624
crossref_primary_10_1016_j_trprot_2014_09_001
crossref_primary_10_1007_s12028_014_0039_z
crossref_primary_10_1016_j_pmrj_2011_03_016
crossref_primary_10_1002_ana_25725
crossref_primary_10_1002_prca_201600003
crossref_primary_10_3109_02699052_2013_860479
crossref_primary_10_3389_fneur_2021_755152
crossref_primary_10_1016_j_expneurol_2021_113865
crossref_primary_10_1093_toxsci_kfu136
crossref_primary_10_1007_s10072_022_06558_y
crossref_primary_10_1016_j_csbj_2015_03_004
crossref_primary_10_1089_neu_2012_2683
crossref_primary_10_1007_s12975_011_0137_6
crossref_primary_10_1186_1559_0275_11_11
crossref_primary_10_3389_fimmu_2019_00686
crossref_primary_10_1007_s40141_017_0146_9
crossref_primary_10_1016_j_tins_2016_03_002
crossref_primary_10_1111_jnc_14678
crossref_primary_10_1016_j_bbr_2016_04_041
crossref_primary_10_1016_j_lfs_2017_11_009
crossref_primary_10_1155_2015_402959
crossref_primary_10_1007_s40263_013_0138_y
crossref_primary_10_1089_neu_2013_2896
crossref_primary_10_1097_JSA_0000000000000117
Cites_doi 10.1089/neu.2006.0029
10.1080/026990500445682
10.1586/14789450.2.4.603
10.1097/00001199-199912000-00009
10.1001/archneur.1991.00530180032013
10.1097/CCM.0b013e3181b788ab
10.1016/S0140-6736(00)02689-1
10.1007/s11064-007-9318-9
10.1097/00006123-200001000-00014
10.1097/00006123-200112000-00056
10.1097/NEN.0b013e3181996bfe
10.1176/jnp.2007.19.1.5
10.1080/02688699944195
10.1016/0006-8993(71)90668-8
10.1089/neu.1995.12.555
10.1111/j.1553-2712.2007.tb02379.x
10.1007/BF01405862
10.1136/bmj.39415.528623.AD
10.1089/neu.1997.14.419
10.1097/00005373-199912000-00026
10.1097/00005373-200204000-00038
10.1007/BF01410977
10.1161/01.STR.22.10.1254
10.1089/neu.2005.22.252
10.1111/j.1365-2990.1996.tb01126.x
10.1089/neu.1997.14.369
10.1089/089771500415391
10.1016/S0140-6736(78)90415-4
10.1016/0140-6736(91)91309-I
10.1016/S0140-6736(94)91712-4
10.1016/S0140-6736(74)91639-0
10.1046/j.1471-4159.2000.0751264.x
10.3171/jns.1981.54.6.0751
10.1097/01.WCB.0000098520.11962.37
10.1097/00006123-199009000-00015
10.1080/026990596124719
10.1089/neu.2006.0224
10.1089/neu.2008.0657
10.1089/neu.2004.21.1131
10.1016/S0140-6736(77)91201-6
10.1111/j.1651-2227.1996.tb14068.x
10.1089/neu.2006.0028
10.3171/sup.1991.75.1s.0s14
10.1089/neu.2004.21.1443
10.1146/annurev.ne.10.030187.001413
10.1097/00005072-199607000-00010
10.1089/neu.2006.003789
10.1001/jama.291.21.2531
10.1136/jnnp.65.6.930
10.1007/s00247-003-0933-6
10.1097/00006123-200112000-00053
10.1227/01.NEU.0000186013.63046.6B
10.3171/jns.1999.91.5.0875
10.1083/jcb.102.6.2088
10.1007/BF03160117
10.1074/jbc.273.35.22490
10.1046/j.1471-4159.2001.00510.x
10.1016/S1053-0770(96)80187-X
10.1080/02688699647104
10.1056/NEJMra072149
10.1097/00006123-199909000-00012
10.3171/JNS-07/10/0792
10.3171/jns.2003.99.4.0666
10.1016/0009-8981(78)90008-6
10.1089/neu.1995.12.565
10.1097/00006123-200112000-00054
10.1089/neu.1999.16.749
10.1016/0304-3940(93)90398-5
10.1016/S0166-2236(99)01479-4
10.1097/00004647-200301000-00004
ContentType Journal Article
Copyright COPYRIGHT 2010 Mary Ann Liebert, Inc.
Copyright 2010, Mary Ann Liebert, Inc.
Copyright_xml – notice: COPYRIGHT 2010 Mary Ann Liebert, Inc.
– notice: Copyright 2010, Mary Ann Liebert, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTPV
AOWAS
D91
DOI 10.1089/neu.2010.1278
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Örebro universitet
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList


MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1557-9042
EndPage 1213
ExternalDocumentID oai_DiVA_org_oru_113425
PMC2942904
A233711920
20408766
10_1089_neu_2010_1278
Genre Research Support, U.S. Gov't, Non-P.H.S
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: NINDS NIH HHS
  grantid: P01-NS38660
– fundername: NINDS NIH HHS
  grantid: R01-NS052831-01
– fundername: NINDS NIH HHS
  grantid: R01 NS051431-01
– fundername: NINDS NIH HHS
  grantid: R01NS049175-01
GroupedDBID ---
.GJ
0R~
0VX
29L
34G
39C
4.4
53G
5GY
5RE
7RV
7X7
88E
8FI
8FJ
AAQQT
AAYXX
ABBKN
ABIVO
ABJNI
ABOCM
ABUWG
ACGFO
ACGFS
ACPRK
ADBBV
ADFRT
AENEX
AFKRA
AFOSN
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BENPR
BNQNF
BPHCQ
BVXVI
CAG
CCPQU
CITATION
COF
CS3
DU5
DWQXO
EBS
EJD
F5P
FYUFA
GNUQQ
HMCUK
IAO
IER
IHR
IM4
IPY
ITC
M1P
M2M
MV1
NAPCQ
NQHIM
O9-
P2P
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
PSYQQ
RIG
RML
RMSOB
UE5
UKHRP
XJT
ZGI
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
7X8
5PM
SCNPE
ADTPV
AOWAS
D91
ID FETCH-LOGICAL-c452t-63a54489c33faf0fcaeebc20369264e55af8cf05555dff4cdd12a2eeb7d8d1e3
ISSN 0897-7151
1557-9042
IngestDate Thu Aug 21 06:38:21 EDT 2025
Thu Aug 21 17:51:39 EDT 2025
Fri Jul 11 06:41:41 EDT 2025
Tue Jun 17 21:56:43 EDT 2025
Tue Jun 10 20:23:30 EDT 2025
Mon Jul 21 05:29:40 EDT 2025
Tue Jul 01 03:35:22 EDT 2025
Thu Apr 24 23:09:22 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License http://www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c452t-63a54489c33faf0fcaeebc20369264e55af8cf05555dff4cdd12a2eeb7d8d1e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 20408766
PQID 734032883
PQPubID 23479
PageCount 11
ParticipantIDs swepub_primary_oai_DiVA_org_oru_113425
pubmedcentral_primary_oai_pubmedcentral_nih_gov_2942904
proquest_miscellaneous_734032883
gale_infotracmisc_A233711920
gale_infotracacademiconefile_A233711920
pubmed_primary_20408766
crossref_citationtrail_10_1089_neu_2010_1278
crossref_primary_10_1089_neu_2010_1278
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-07-01
PublicationDateYYYYMMDD 2010-07-01
PublicationDate_xml – month: 07
  year: 2010
  text: 2010-07-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA
PublicationTitle Journal of neurotrauma
PublicationTitleAlternate J Neurotrauma
PublicationYear 2010
Publisher Mary Ann Liebert, Inc
Publisher_xml – name: Mary Ann Liebert, Inc
References B20
B64
B21
B65
B22
B66
B67
B24
B68
B25
B69
B26
Balestreri M. (B4) 2004; 75
B28
Papa L. (B51) 2008; 28
Choi S.C. (B15) 1996
Graham D.I. (B23) 1997
B70
B71
B72
B30
B74
B31
B75
B32
B76
B33
B77
B34
B78
B35
B79
B36
B37
B38
Farkas O. (B19) 2005; 1478
B1
B2
B3
B5
B6
B7
B8
B9
B80
B81
B82
Cardali S. (B14) 2006; 50
B83
B40
B42
Bruns J. (B12) 2009; 44
B43
B44
B46
B47
B48
B49
Xiong H. (B84) 2000; 31
Johnson A.M. (B29) 1999
Stein S.C. (B73) 1996
B50
B52
B53
B10
B54
B11
B55
Marshall L.F. (B41) 1991; 75
B56
B13
B57
B58
B59
B16
Eng L.F. (B17) 1980
B18
Marion D.W. (B39) 1996
McKeating E.G. (B45) 1998; 71
Jennett B. (B27) 1975; 9
B60
B61
B62
B63
References_xml – start-page: 779
  volume-title: Neurotrauma
  year: 1996
  ident: B15
– ident: B40
  doi: 10.1089/neu.2006.0029
– ident: B31
  doi: 10.1080/026990500445682
– volume: 1478
  start-page: 855
  year: 2005
  ident: B19
  publication-title: Acta Neurochir. Wien.
– ident: B79
  doi: 10.1586/14789450.2.4.603
– start-page: 767
  volume-title: Neurotrauma
  year: 1996
  ident: B39
– ident: B78
  doi: 10.1097/00001199-199912000-00009
– start-page: 31
  volume-title: Neurotrauma
  year: 1996
  ident: B73
– ident: B34
  doi: 10.1001/archneur.1991.00530180032013
– ident: B50
  doi: 10.1097/CCM.0b013e3181b788ab
– ident: B22
  doi: 10.1016/S0140-6736(00)02689-1
– ident: B70
  doi: 10.1007/s11064-007-9318-9
– ident: B71
  doi: 10.1097/00006123-200001000-00014
– ident: B2
  doi: 10.1097/00006123-200112000-00056
– ident: B44
  doi: 10.1097/NEN.0b013e3181996bfe
– ident: B6
  doi: 10.1176/jnp.2007.19.1.5
– ident: B57
  doi: 10.1080/02688699944195
– ident: B18
  doi: 10.1016/0006-8993(71)90668-8
– ident: B55
  doi: 10.1089/neu.1995.12.555
– ident: B13
  doi: 10.1111/j.1553-2712.2007.tb02379.x
– start-page: 197
  volume-title: Greenfields Neuropathology
  year: 1997
  ident: B23
– ident: B75
  doi: 10.1007/BF01405862
– ident: B32
  doi: 10.1136/bmj.39415.528623.AD
– ident: B42
  doi: 10.1089/neu.1997.14.419
– ident: B83
  doi: 10.1097/00005373-199912000-00026
– ident: B26
  doi: 10.1097/00005373-200204000-00038
– ident: B82
  doi: 10.1007/BF01410977
– volume: 50
  start-page: 25
  year: 2006
  ident: B14
  publication-title: J. Neurosurg. Sci.
– ident: B3
  doi: 10.1161/01.STR.22.10.1254
– ident: B24
  doi: 10.1089/neu.2005.22.252
– ident: B20
  doi: 10.1111/j.1365-2990.1996.tb01126.x
– ident: B48
  doi: 10.1089/neu.1997.14.369
– volume: 71
  start-page: 117
  year: 1998
  ident: B45
  publication-title: Acta Neurochir. Suppl. Wien.
– volume: 9
  start-page: 231
  year: 1975
  ident: B27
  publication-title: J R Coll Physicians Land.
– ident: B64
  doi: 10.1089/089771500415391
– ident: B77
  doi: 10.1016/S0140-6736(78)90415-4
– ident: B67
  doi: 10.1016/0140-6736(91)91309-I
– ident: B8
  doi: 10.1016/S0140-6736(94)91712-4
– ident: B76
  doi: 10.1016/S0140-6736(74)91639-0
– ident: B5
  doi: 10.1046/j.1471-4159.2000.0751264.x
– ident: B47
  doi: 10.3171/jns.1981.54.6.0751
– ident: B53
  doi: 10.1097/01.WCB.0000098520.11962.37
– ident: B33
  doi: 10.1097/00006123-199009000-00015
– ident: B72
  doi: 10.1080/026990596124719
– ident: B1
  doi: 10.1089/neu.2006.0224
– ident: B11
  doi: 10.1089/neu.2008.0657
– ident: B74
  doi: 10.1089/neu.2004.21.1131
– ident: B28
  doi: 10.1016/S0140-6736(77)91201-6
– ident: B7
  doi: 10.1111/j.1651-2227.1996.tb14068.x
– start-page: 85
  volume-title: Proteins of the Nervous System
  year: 1980
  ident: B17
– ident: B46
  doi: 10.1089/neu.2006.0028
– volume: 75
  start-page: S14
  year: 1991
  ident: B41
  publication-title: J. Neurosurg.
  doi: 10.3171/sup.1991.75.1s.0s14
– ident: B61
  doi: 10.1089/neu.2004.21.1443
– ident: B38
  doi: 10.1146/annurev.ne.10.030187.001413
– ident: B69
  doi: 10.1097/00005072-199607000-00010
– ident: B54
  doi: 10.1089/neu.2006.003789
– ident: B16
  doi: 10.1001/jama.291.21.2531
– ident: B59
  doi: 10.1136/jnnp.65.6.930
– ident: B62
  doi: 10.1007/s00247-003-0933-6
– ident: B63
  doi: 10.1097/00006123-200112000-00053
– volume: 75
  start-page: 161
  year: 2004
  ident: B4
  publication-title: J. Neurol. Neurosurg. Psychiatry
– ident: B37
  doi: 10.1227/01.NEU.0000186013.63046.6B
– ident: B56
  doi: 10.3171/jns.1999.91.5.0875
– ident: B60
  doi: 10.1083/jcb.102.6.2088
– start-page: 516
  volume-title: Tietz Textbook of Clinical Chemistry
  year: 1999
  ident: B29
– ident: B36
  doi: 10.1007/BF03160117
– ident: B80
  doi: 10.1074/jbc.273.35.22490
– ident: B52
  doi: 10.1046/j.1471-4159.2001.00510.x
– volume: 44
  start-page: 2
  issue: 10
  year: 2009
  ident: B12
  publication-title: Epilepsia
– ident: B30
  doi: 10.1016/S1053-0770(96)80187-X
– ident: B65
  doi: 10.1080/02688699647104
– volume: 28
  start-page: 1
  year: 2008
  ident: B51
  publication-title: Expert Opin. Med. Diagn.
– ident: B10
  doi: 10.1056/NEJMra072149
– ident: B58
  doi: 10.1097/00006123-199909000-00012
– ident: B35
  doi: 10.3171/JNS-07/10/0792
– ident: B25
  doi: 10.3171/jns.2003.99.4.0666
– ident: B49
  doi: 10.1016/0009-8981(78)90008-6
– ident: B9
  doi: 10.1089/neu.1995.12.565
– ident: B66
  doi: 10.1097/00006123-200112000-00054
– ident: B43
  doi: 10.1089/neu.1999.16.749
– ident: B21
  doi: 10.1016/0304-3940(93)90398-5
– ident: B81
  doi: 10.1016/S0166-2236(99)01479-4
– ident: B68
  doi: 10.1097/00004647-200301000-00004
– volume: 31
  start-page: 217
  year: 2000
  ident: B84
  publication-title: Sheng Li Ke Xue Jin Zhan
SSID ssj0013627
Score 2.386225
Snippet In this study we assessed the clinical utility of quantitative assessments of alphaII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120...
In this study we assessed the clinical utility of quantitative assessments of all-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120...
In this study we assessed the clinical utility of quantitative assessments of αII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120...
SourceID swepub
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1203
SubjectTerms Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers - cerebrospinal fluid
Brain
Brain Injuries - cerebrospinal fluid
Brain Injuries - diagnosis
Brain Injuries - mortality
Cerebrospinal fluid
Female
Humans
Injuries
Male
Middle Aged
Original
Peptide Fragments - cerebrospinal fluid
Physiological aspects
Predictive Value of Tests
Prognosis
Protein Isoforms - cerebrospinal fluid
Severity of Illness Index
Spectrin - cerebrospinal fluid
Survival Rate
Young Adult
Title αII-Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe Traumatic Brain Injury Patients
URI https://www.ncbi.nlm.nih.gov/pubmed/20408766
https://www.proquest.com/docview/734032883
https://pubmed.ncbi.nlm.nih.gov/PMC2942904
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-113425
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaW9sIFgXgtlMoHykMlS-I8nHDb7S60SC0Vu6DeIsdxILTKom1y4U8h_gi_iRk7SZPVIhUOG21iT17zZTy2Zz4T8hTa5IhlobQinijL44JZ4EZEVpB4MhMBS8IEk5OPT4LDT977M_9sMPjZiVqqymQkf2zMK_kfrcIx0Ctmyf6DZtuTwgH4D_qFLWgYttfS8d7BbG_iHB1ZuIp8ucoLUJUS5yn0rDEDAKlc9aDqfDI9BX1F2P2fmti63HAzf6hKuDFNHDJX8PwK2c4rQ-M6wdUjwIB8g9eOVP55Q_u0wZnVtJilFm1VuCzSZmZnXqpMFHlbhlln8lKd12VgcPfHozYUSCTQf78weds64LI7aFDD4t1K463YPx51By5wzp03Axe1fYu4xZ2ab1bV9tfnVmR7PQNtyANqIPKOtXWY7XZabmSn29gqwJWQZVZVJpTPYWbVoD779lqr2MYq6ln6MIpBPEbxGMVvkG0G_RI0rPyMX01bBWaN4ObJalJX2H_du3rPCVp3BTq-0Hqcbo_NVntAi9vkVq1tOjY4vEMGqrhL8t-_OvijLf5ogz_6QqPv5RvaIo8C8miNPApCBnm0RR7VyKMGebRB3j2yeDtbHBxa9fIdlvR8VlqBK3zo_EfSdTOR2ZkUSiUSJ74j8MKV7wuwERkSzvlplnkyTR0mGNThaZg6yr1PtoploR4SKqTr8ywMfZU6ni9BUKSRJ3wWqNQWdjYkr5rXGcua2h5XWLmINypvSJ611b8bTpe_VXyOuokRTHA-KeqUFbgrZE2Lx8x1uQN9JHtIdno1wUbLXjFttBtjEQY2FmpZXcbc9ZDRMnSH5IFRdntLDNpX8FWCIeE9GLQVkBm-X1LkXzVDPIvAzbQ9eFADmJ7INP88jperL_CrYsdxodV-dN038pjcvPqUd8hWuarUE_DKy2RXfwm7ZHsyOzn9-Adm0uW8
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%CE%B1II-Spectrin+Breakdown+Products+%28SBDPs%29%3A+Diagnosis+and+Outcome+in+Severe+Traumatic+Brain+Injury+Patients&rft.jtitle=Journal+of+neurotrauma&rft.au=Mondello%2C+Stefania&rft.au=Robicsek%2C+Steven+A.&rft.au=Gabrielli%2C+Andrea&rft.au=Brophy%2C+Gretchen+M.&rft.date=2010-07-01&rft.issn=0897-7151&rft.eissn=1557-9042&rft.volume=27&rft.issue=7&rft.spage=1203&rft.epage=1213&rft_id=info:doi/10.1089%2Fneu.2010.1278&rft.externalDBID=n%2Fa&rft.externalDocID=10_1089_neu_2010_1278
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0897-7151&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0897-7151&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0897-7151&client=summon